(4-Methyl-2-oxochromen-7-yl) furan-2-carboxylate is a complex organic compound with potential applications in various fields, including:
**1. Medicinal Chemistry:**
* **Anti-cancer activity:** Studies have shown that this compound exhibits anti-cancer activity against various cell lines, potentially by inhibiting the growth and proliferation of cancer cells.
* **Anti-inflammatory activity:** Some research suggests that it may possess anti-inflammatory properties, which could be valuable in treating inflammatory conditions.
* **Antibacterial activity:** This compound has also shown promising results in inhibiting the growth of certain bacteria, opening possibilities for its use as an antibiotic.
**2. Materials Science:**
* **Organic electronics:** The compound's unique structure and properties could be beneficial in the development of organic electronic devices, like solar cells and organic light-emitting diodes (OLEDs).
* **Dye synthesis:** It can serve as a building block for synthesizing new dyes with specific colors and properties, which could have applications in textiles, printing, and other industries.
**3. Agricultural Chemistry:**
* **Pesticide development:** The compound's potential to interfere with biological processes could be explored for developing novel pesticides that target specific pests.
**Important Research Aspects:**
* **Structure-activity relationship studies:** Researchers are interested in understanding how the structure of this compound influences its biological activity. This knowledge can be used to design even more potent and specific derivatives.
* **Mechanism of action:** Determining how this compound interacts with biological targets (e.g., enzymes, proteins) is crucial for optimizing its therapeutic and other applications.
* **Synthesis and optimization:** Developing efficient and scalable synthetic routes for the compound and its derivatives is essential for making it readily available for further research and potential commercialization.
* **Toxicity and safety:** Thorough toxicological studies are necessary to assess the potential risks associated with using this compound and to ensure its safe application.
Overall, (4-Methyl-2-oxochromen-7-yl) furan-2-carboxylate is a promising compound with potential applications in various fields. Continued research is needed to fully understand its properties, optimize its synthesis, and explore its full potential.
ID Source | ID |
---|---|
PubMed CID | 728528 |
CHEMBL ID | 1327635 |
CHEBI ID | 149799 |
Synonym |
---|
MLS000712758 , |
smr000282525 |
EU-0035339 |
CBDIVE_012489 |
OPREA1_783928 |
OPREA1_667731 |
CHEMDIV2_000087 |
AKOS000536547 |
HMS1369D21 |
CHEBI:149799 |
(4-methyl-2-oxochromen-7-yl) furan-2-carboxylate |
HMS2681I03 |
4-methyl-2-oxo-2h-chromen-7-yl furan-2-carboxylate |
CCG-15673 |
2-furancarboxylic acid, 4-methyl-2-oxo-2h-1-benzopyran-7-yl ester |
87468-02-8 |
STL457259 |
CHEMBL1327635 |
furan-2-carboxylic acid (2-keto-4-methyl-chromen-7-yl) ester |
2-furancarboxylic acid (4-methyl-2-oxo-1-benzopyran-7-yl) ester |
bdbm32909 |
cid_728528 |
(4-methyl-2-oxidanylidene-chromen-7-yl) furan-2-carboxylate |
SR-01000404506-1 |
sr-01000404506 |
DTXSID60352517 |
4-methyl-2-oxo-2h-chromen-7-yl 2-furoate |
Role | Description |
---|---|
anticoronaviral agent | Any antiviral agent which inhibits the activity of coronaviruses. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
coumarins | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.4467 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 16.9441 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 7.9433 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 75.1137 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 12.5893 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 31.6228 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
geminin | Homo sapiens (human) | Potency | 6.5131 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
Vpr | Human immunodeficiency virus 1 | Potency | 63.0957 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1.0000 | 10.4756 | 28.1838 | AID1457 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
coagulation factor XI | Homo sapiens (human) | IC50 (µMol) | 0.0497 | 0.0497 | 1.4500 | 3.5062 | AID846 |
prothrombin | Homo sapiens (human) | IC50 (µMol) | 0.9487 | 0.0010 | 3.3170 | 14.6895 | AID1215 |
3C-like protease, partial | Infectious bronchitis virus | IC50 (µMol) | 3.3410 | 1.0850 | 5.6067 | 9.8110 | AID1890 |
Coagulation factor XII | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0104 | 3.8890 | 10.9666 | AID852 |
Neutrophil elastase | Homo sapiens (human) | IC50 (µMol) | 0.0497 | 0.0063 | 2.0734 | 22.3780 | AID846 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
serine-type endopeptidase activity | Coagulation factor XII | Homo sapiens (human) |
calcium ion binding | Coagulation factor XII | Homo sapiens (human) |
protein binding | Coagulation factor XII | Homo sapiens (human) |
misfolded protein binding | Coagulation factor XII | Homo sapiens (human) |
protease binding | Neutrophil elastase | Homo sapiens (human) |
transcription corepressor activity | Neutrophil elastase | Homo sapiens (human) |
endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
serine-type endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
protein binding | Neutrophil elastase | Homo sapiens (human) |
heparin binding | Neutrophil elastase | Homo sapiens (human) |
peptidase activity | Neutrophil elastase | Homo sapiens (human) |
cytokine binding | Neutrophil elastase | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |